A Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of CD2027 3 microg/g Oily Spray Applied Twice Daily for 8 Weeks in Subjects With Plaque-Type Psoriasis.

Trial Profile

A Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of CD2027 3 microg/g Oily Spray Applied Twice Daily for 8 Weeks in Subjects With Plaque-Type Psoriasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2012

At a glance

  • Drugs Calcitriol (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Galderma
  • Most Recent Events

    • 27 Oct 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top